Academic Journal
Immune cell fibrotic plasticity: mesenchymal-like reprogramming of macrophages, neutrophils and T cells.
| Τίτλος: | Immune cell fibrotic plasticity: mesenchymal-like reprogramming of macrophages, neutrophils and T cells. |
|---|---|
| Συγγραφείς: | Long X; Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi Guizhou, China., Yuan S; Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi Guizhou, China., Luo Z; Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi Guizhou, China., Chen Y; Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi Guizhou, China., Xiao S; Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi Guizhou, China., Deng C; Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi Guizhou, China., Chen J; Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi Guizhou, China. |
| Πηγή: | Frontiers in immunology [Front Immunol] 2026 Oct 02; Vol. 17, pp. 1904807. Date of Electronic Publication: 2026 Oct 02 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Ιατρικοί όροι (MeSH): | Macrophages*/immunology , Macrophages*/pathology , Macrophages*/metabolism , Neutrophils*/immunology , Neutrophils*/pathology , Neutrophils*/metabolism , T-Lymphocytes*/immunology , T-Lymphocytes*/pathology , T-Lymphocytes*/metabolism , Cell Plasticity*/immunology , Cellular Reprogramming*/immunology, Humans ; Animals ; Fibrosis ; Signal Transduction |
| Περίληψη: | Fibrosis has traditionally been viewed as a fibroblast- and myofibroblast-centred process, in which immune cells regulate matrix deposition primarily through inflammatory mediators and paracrine signalling. However, advances in single-cell profiling, spatial analyses and lineage-resolved approaches are beginning to challenge this rigid division of cellular labour. Emerging evidence indicates that, in persistently injured and maladaptively repairing tissues, selected immune cell populations can acquire matrix producing, cytoskeletal remodelling and mesenchymal-like functions, thereby contributing more directly to structural tissue remodelling. In this Review, we introduce the concept of immune cell fibrotic plasticity and critically assess the evidence, regulatory mechanisms and pathological significance of fibrotic effector states in macrophages, neutrophils and T cells. Macrophage reprogramming towards myofibroblast-like states appears to be shaped by convergent TGF-β/SMAD signalling, metabolic adaptation and epigenetic regulation. Neutrophils can synthesize, transport and organize extracellular matrix, conferring temporally distinct functions in tissue stabilization and pathological scarring. Evidence for mesenchymal-like reprogramming of T cells remains limited, but raises the possibility that adaptive immune cells can also acquire structural effector functions. Importantly, co-expression of immune and mesenchymal markers does not, by itself, establish stable lineage conversion. These phenomena are more appropriately understood as microenvironmentally induced, context-dependent functional states rather than universal or complete transdifferentiation. Defining the origins, reversibility and quantitative contribution of these states will determine whether immune-cell fibrotic plasticity can be exploited for disease stratification and the development of more selective antifibrotic therapies. (Copyright © 2026 Long, Yuan, Luo, Chen, Xiao, Deng and Chen.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Eur J Pharmacol. 2026 Feb 15;1015:178567. (PMID: 41565196) Hepatology. 2015 Jun;61(6):2067-79. (PMID: 25711908) J Neuroinflammation. 2020 Nov 25;17(1):355. (PMID: 33239022) Front Pharmacol. 2021 Feb 24;12:620433. (PMID: 33716747) J Inflamm Res. 2024 Feb 17;17:1083-1094. (PMID: 38384372) Nat Rev Dis Primers. 2021 May 6;7(1):31. (PMID: 33958600) Nat Commun. 2024 Mar 5;15(1):1995. (PMID: 38443404) Nat Commun. 2018 May 17;9(1):1970. (PMID: 29773802) Cell Signal. 2026 Feb;138:112261. (PMID: 41270813) Cell Death Dis. 2022 Aug 8;13(8):693. (PMID: 35941120) Front Pharmacol. 2026 Jan 30;17:1739457. (PMID: 41693769) Ophthalmology. 2025 Apr;132(4):P1-P74. (PMID: 39918524) Arch Med Res. 2025 Jun;56(4):103173. (PMID: 39778307) Front Immunol. 2025 Aug 01;16:1620571. (PMID: 40821816) Int J Biol Sci. 2026 Feb 04;22(5):2361-2382. (PMID: 41800255) Cell Mol Immunol. 2026 Feb;23(2):123-149. (PMID: 41530536) Nat Rev Nephrol. 2025 May;21(5):314-329. (PMID: 39934355) Ren Fail. 2024 Dec;46(1):2327498. (PMID: 38666363) Commun Biol. 2025 Feb 22;8(1):286. (PMID: 39987296) FASEB J. 2013 Mar;27(3):1114-26. (PMID: 23193171) Thromb Haemost. 2015 Mar;113(3):473-81. (PMID: 25589344) Nat Commun. 2025 Nov 26;16(1):11655. (PMID: 41298466) Signal Transduct Target Ther. 2023 May 22;8(1):207. (PMID: 37211559) Nat Rev Immunol. 2025 Nov;25(11):816-830. (PMID: 40467841) Trends Genet. 2017 Dec;33(12):943-959. (PMID: 28919019) Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20741-20752. (PMID: 32788346) Front Immunol. 2025 Aug 13;16:1625972. (PMID: 40881699) Adv Sci (Weinh). 2025 Mar;12(11):e2412123. (PMID: 39869489) Oncotarget. 2016 Feb 23;7(8):8809-22. (PMID: 26684242) Inflammation. 2024 Dec;47(6):2094-2107. (PMID: 38662165) Nat Commun. 2026 Apr 20;:. (PMID: 42010242) Int Immunopharmacol. 2026 May 01;176:116511. (PMID: 41833105) Front Immunol. 2026 Jul 01;17:1891187. (PMID: 42459665) Front Oncol. 2026 Jan 12;15:1676803. (PMID: 41602404) Front Immunol. 2026 Jun 09;17:1834346. (PMID: 42344934) Transplant Cell Ther. 2026 Apr;32(4):454-465. (PMID: 41429336) Exp Mol Med. 2025 Apr;57(4):759-774. (PMID: 40164683) J Clin Invest. 1991 Feb;87(2):619-23. (PMID: 1991845) Nat Rev Dis Primers. 2017 Oct 20;3:17074. (PMID: 29052582) Int Immunopharmacol. 2021 Apr;93:107396. (PMID: 33540244) Cell Discov. 2022 Jun 21;8(1):58. (PMID: 35725971) J Crohns Colitis. 2025 Jan 11;19(1):. (PMID: 39126198) Animal Model Exp Med. 2025 Feb;8(2):363-371. (PMID: 38979656) Immunity. 2021 May 11;54(5):903-915. (PMID: 33979587) Exp Mol Med. 2022 May;54(5):673-684. (PMID: 35624154) J Neuroinflammation. 2026 Apr 30;23(1):. (PMID: 42063159) Front Genet. 2025 Jul 03;16:1560471. (PMID: 40678385) Basic Res Cardiol. 2019 Aug 15;114(5):37. (PMID: 31418072) Eur Heart J. 2025 Jun 16;46(23):2223-2238. (PMID: 39969161) Exp Mol Med. 2024 Sep;56(9):2052-2064. (PMID: 39261656) Front Immunol. 2020 Sep 30;11:566535. (PMID: 33101287) Int J Biol Sci. 2025 Jan 06;21(3):940-954. (PMID: 39897045) Nat Rev Immunol. 2023 May;23(5):274-288. (PMID: 36257987) Nat Rev Immunol. 2014 Jun;14(6):392-404. (PMID: 24854589) EBioMedicine. 2018 Dec;38:283-291. (PMID: 30473378) Int J Mol Sci. 2025 Sep 05;26(17):. (PMID: 40943586) Nat Immunol. 2023 Sep;24(9):1423-1433. (PMID: 37474654) Biochem Biophys Res Commun. 2026 May 28;815:153640. (PMID: 41916009) Cell Death Dis. 2025 May 10;16(1):372. (PMID: 40348745) Nat Commun. 2017 Feb 10;8:14345. (PMID: 28186091) Nat Rev Immunol. 2026 Apr;26(4):314-325. (PMID: 41152441) Int Immunopharmacol. 2025 Feb 20;148:114087. (PMID: 39818090) J Breast Cancer. 2023 Feb;26(1):46-59. (PMID: 36762782) Nat Immunol. 2024 Dec;25(12):2209-2219. (PMID: 39567761) Nat Immunol. 2022 Apr;23(4):518-531. (PMID: 35354953) J Invest Dermatol. 2018 Feb;138(2):325-335. (PMID: 28942366) Nature. 2025 May;641(8063):740-748. (PMID: 40108463) Signal Transduct Target Ther. 2023 Mar 17;8(1):129. (PMID: 36932062) Nat Rev Nephrol. 2024 Jul;20(7):473-485. (PMID: 38570631) Adv Sci (Weinh). 2026 Aug;13(47):e75620. (PMID: 42133197) Inflamm Res. 2023 Dec;72(12):2111-2126. (PMID: 37924395) Clin Exp Allergy. 2002 Feb;32(2):237-46. (PMID: 11929488) Adv Healthc Mater. 2023 Apr;12(11):e2203076. (PMID: 36603196) Int J Exp Pathol. 1994 Dec;75(6):397-404. (PMID: 7734329) Front Cell Dev Biol. 2026 Jan 06;13:1727624. (PMID: 41567981) Nat Commun. 2025 Dec 21;17(1):653. (PMID: 41423454) iScience. 2023 May 06;26(6):106822. (PMID: 37250774) Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. (PMID: 35486072) Nat Commun. 2026 May 14;17(1):. (PMID: 42135322) J Inflamm Res. 2026 May 12;19:555306. (PMID: 42152944) Nat Rev Immunol. 2015 Dec;15(12):731-44. (PMID: 26603899) Arthritis Res Ther. 2013 Oct 28;15(5):R168. (PMID: 24289101) J Reconstr Microsurg. 2026 Jul;42(6):466-472. (PMID: 40840541) Phytomedicine. 2025 Jan;136:156324. (PMID: 39700636) Mol Ther. 2022 Sep 7;30(9):3017-3033. (PMID: 35791881) Cell Syst. 2019 Apr 24;8(4):329-337.e4. (PMID: 30954475) Biochem Biophys Res Commun. 2026 Apr 09;808:153453. (PMID: 41719615) Int Immunopharmacol. 2025 Jan 27;146:113873. (PMID: 39693954) Nat Biotechnol. 2014 Apr;32(4):381-386. (PMID: 24658644) J Transl Med. 2025 Feb 28;23(1):251. (PMID: 40022123) Int J Biol Sci. 2026 Apr 23;22(9):4705-4723. (PMID: 42157945) Annu Rev Pathol. 2024 Jan 24;19:227-259. (PMID: 38265879) Immunity. 2021 Jul 13;54(7):1377-1391. (PMID: 34260886) Adv Sci (Weinh). 2025 Nov;12(43):e12571. (PMID: 40874461) Cell Death Dis. 2016 Dec 1;7(12):e2495. (PMID: 27906172) Br J Pharmacol. 2026 Sep;183(17):5190-5210. (PMID: 42204873) Arthritis Rheumatol. 2017 May;69(5):1078-1089. (PMID: 27992693) J Pathol. 2014 Jul;233(3):294-307. (PMID: 24740698) Transl Res. 2019 Apr;206:57-70. (PMID: 30633890) JAMA. 2024 Jan 9;331(2):147-157. (PMID: 38193957) FASEB J. 2025 Sep 15;39(17):e71008. (PMID: 40923203) Invest Ophthalmol Vis Sci. 2025 Jun 2;66(6):47. (PMID: 40521981) Eur Respir J. 2023 Mar 30;61(3):. (PMID: 36517177) J Immunol. 1989 Sep 15;143(6):1961-8. (PMID: 2778318) Int J Biol Sci. 2025 Aug 16;21(12):5287-5304. (PMID: 40959267) Nat Rev Immunol. 2023 Sep;23(9):563-579. (PMID: 36922638) Clin Immunol. 2016 Mar;164:78-84. (PMID: 26854617) Nat Rev Nephrol. 2025 Mar;21(3):200-215. (PMID: 39548215) Biomaterials. 2026 May;328:123861. (PMID: 41274262) Eur Cell Mater. 2010 Oct 07;20:197-209. (PMID: 20931490) J Clin Invest. 2022 Jun 15;132(12):. (PMID: 35482420) J Clin Invest. 2025 Oct 1;135(19):. (PMID: 41031892) J Mol Med (Berl). 2000;78(6):337-45. (PMID: 11001531) Nephrol Dial Transplant. 2019 Oct 1;34(10):1657-1668. (PMID: 30590718) Adv Sci (Weinh). 2026 Feb;13(11):e02727. (PMID: 41211625) J Am Soc Nephrol. 2017 Jul;28(7):2053-2067. (PMID: 28209809) Kidney Int. 2024 Apr;105(4S):S117-S314. (PMID: 38490803) Int J Biol Macromol. 2024 Oct;278(Pt 2):134491. (PMID: 39111495) |
| Contributed Indexing: | Keywords: T cell; fibrosis; macrophages; mesenchymal transition; neutrophil |
| Entry Date(s): | Date Created: 20261017 Date Completed: 20261017 Latest Revision: 20261019 |
| Update Code: | 20261019 |
| PubMed Central ID: | PMC13673658 |
| DOI: | 10.3389/fimmu.2026.1904807 |
| PMID: | 42891187 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!